9. Pleural Diseases (Effusion, Parapneumonic Effusion/Empyema, Malignant Effusion)

Quick Recap

Nests under Acute Respiratory Failure. Focus: pleural effusion evaluation, parapneumonic effusion/empyema, and malignant effusion. Pneumothorax is covered as its own protocol.

1. Definition

Pleural effusion = pathological accumulation of fluid in the pleural space (normally a thin lubricating film). Classified by mechanism (transudate vs exudate, Section 2) and by underlying cause: parapneumonic (associated with bacterial pneumonia/lung abscess/bronchiectasis, may progress to empyema), malignant, or other (chylothorax, hemothorax, urinothorax, etc.).

2. Pathophysiology

Pleural fluid normally forms by filtration from high-pressure systemic (parietal pleural) vessels and drains via parietal lymphatics. Effusions arise when production exceeds drainage capacity, via four broad mechanisms: increased hydrostatic pressure (heart failure -> transudate), decreased oncotic pressure (hypoalbuminemia -> transudate), increased capillary permeability (infection/inflammation/malignancy -> exudate), or impaired lymphatic drainage (malignancy, lymphatic obstruction -> exudate, sometimes chylous).

Parapneumonic effusion staging: exudative (early, sterile, simple) -> fibrinopurulent (bacterial invasion, fibrin deposition, loculation beginning) -> organizing (fibroblast proliferation, thick pleural peel, "trapped lung" risk). Only the fibrinopurulent/organizing (complicated) stages and frank empyema require more than antibiotics alone — this staging distinction drives the entire management algorithm.

3. Immediate Stabilization (ABCDE)

Most pleural effusions are not immediately life-threatening unless large enough to cause respiratory compromise (mediastinal shift, restrictive physiology) or represent a rapidly accumulating hemothorax/empyema with sepsis physiology.

Breathing: supplemental O2 as needed; therapeutic thoracentesis for large, symptomatic effusions causing respiratory distress.

Circulation: treat septic shock physiology aggressively if empyema/complicated parapneumonic effusion is the source (source control via drainage is part of resuscitation, not just definitive therapy).

Checklist:

4. Focused History

Underlying cardiac/renal/hepatic disease (transudate risk), recent pneumonia/fever (parapneumonic), known malignancy (Section 11), recent trauma/procedure (hemothorax, iatrogenic), autoimmune disease (rheumatoid/lupus pleuritis), TB exposure/risk factors, recent esophageal instrumentation or vomiting (esophageal rupture -> salivary amylase-positive effusion), renal disease/urologic procedure (urinothorax).

5. Examination + POCUS

Decreased breath sounds, dullness to percussion, decreased tactile fremitus, asymmetric diaphragmatic excursion.

POCUS is central to both diagnosis and procedural guidance: confirms presence and estimates volume, distinguishes free-flowing from loculated fluid, and can suggest fluid character (anechoic = likely simple transudate/early exudate; complex septated/echogenic = more likely empyema/hemothorax/malignant). Ultrasound-guided thoracentesis is standard of care (BTS guidelines) and reduces complication/hemorrhage risk, and can be performed safely even in mechanically ventilated patients.

6. Syndrome Identification

Pleural space process — first distinguish transudate vs exudate (changes the entire differential), then determine if this is a simple, uncomplicated effusion vs a complicated parapneumonic effusion/empyema requiring urgent drainage (Section 11), vs a malignant effusion requiring a different long-term strategy (Section 12).

7. Differential Diagnosis

8. Severity Assessment

No single dedicated severity score for effusions generally; severity is determined by (1) degree of respiratory compromise, (2) presence of sepsis physiology if infectious, and (3) the specific complicated parapneumonic effusion/empyema criteria (Section 11), which function as the key risk-stratification and treatment-threshold tool for the most common ICU-relevant pleural pathology.

9. Investigations

Indications for thoracentesis: pleural effusion of unknown etiology, fever in the setting of a long-standing effusion, air-fluid level in the pleural space, rapid change in effusion size, concern for developing empyema.

Fluid analysis:

• Light's criteria (exudate if any one met): pleural fluid:serum protein ratio >0.5; pleural fluid:serum LDH ratio >0.6; pleural fluid LDH >2/3 upper limit of normal serum LDH. Sensitivity 97.9%.
• Heffner's criteria (alternative, no paired serum draw needed): pleural fluid protein >2.9 g/dL; pleural fluid LDH >0.45x upper limit of normal. Sensitivity 98.4%, similar performance to Light's.
• Targeted additional tests: cytology (malignancy), Gram stain/culture (infection), AFB + pleural ADA >70 U/L (TB), rheumatoid factor/RA cells (rheumatoid effusion), triglycerides/chylomicrons (chylothorax), salivary amylase (esophageal rupture), pleural:serum creatinine ratio (urinothorax)

Thoracentesis technique: ultrasound-guided is standard of care; safe with >2cm fluid on ultrasound, even in ventilated patients; can be diagnostic (small volume) or therapeutic (>1500 mL); if ultrasound unavailable, at least 1cm layering fluid on lateral decubitus film needed for safe blind approach; ultrasound assistance recommended after two "dry taps." No strong data that uncorrected coagulopathy (PT/PTT >2x normal, INR >1.5, platelets <50,000) increases hemorrhagic risk, but risk/benefit should still be individually weighed, especially for urgent procedures.

Imaging: ultrasound for bedside characterization/procedural guidance; CT chest (non-contrast for fluid volume/loculation assessment obscured on CXR; contrast for pleural surface abnormality suggesting empyema/malignancy; PE-protocol contrast if PE is the suspected cause) — CT cannot be done at bedside, a real limitation in unstable ICU patients.

~20% of effusions remain idiopathic despite full workup — if the patient is not clinically deteriorating, a conservative watch-and-wait approach (with serial thoracenteses if needed) is reasonable before escalating to thoracoscopy.

10. POCUS

See Section 5. Use consistently for procedural guidance regardless of experience level — reduces hemorrhagic complications per BTS guidance and is now standard of care.

11. Evidence-Based Management — Parapneumonic Effusion / Empyema (highest ICU relevance)

The central decision is uncomplicated (antibiotics + observation/simple thoracentesis) vs complicated (requires tube thoracostomy).

Indications for tube thoracostomy in parapneumonic effusion (any one triggers drainage):

• Radiographic: pleural fluid loculation; effusion filling more than half the hemithorax; air-fluid level present
• Microbiologic: frank pus in the pleural space; positive Gram stain; positive pleural fluid culture
• Chemical: pleural fluid pH <7.2; pleural fluid glucose <60 mg/dL

Once drainage is indicated:

• Chest tube size: 8-14F (image-assisted guidewire) for most complicated parapneumonic effusions; >=20F (guidewire or blunt dissection) reasonable depending on clinical situation and operator expertise, especially for frank empyema with thick pus
• Intrapleural fibrinolytics + DNase (e.g., tPA + DNase, twice daily x3 days) improves drainage, reduces need for surgical therapy, and shortens length of stay compared to either agent alone or tube drainage alone — consider early if loculated/complicated
• If intrapleural therapy fails: escalate to thoracoscopy (VATS) with adhesiolysis, or thoracotomy with decortication for organized/chronic empyema

Antibiotics: guided by the underlying pneumonia source (see Severe Pneumonia protocol); do not withhold pending drainage decision.

12. Evidence-Based Management — Malignant Pleural Effusion

Most common primaries: lung (38%), breast (17%), lymphoma (12%), unknown primary (11%), GU (9%), GI (7%). Mechanism: pleural metastasis increasing permeability and/or lymphatic obstruction impairing drainage — effusions are often large and recurrent.

Management ladder (recurrence is the default expectation, so simple thoracentesis alone is rarely definitive):

• Simple thoracentesis: symptom relief only, high recurrence rate
• Chest tube + pleurodesis: obliterates pleural space to prevent recurrence — reasonable for patients with reasonable life expectancy and re-expandable lung
• Indwelling pleural catheter (tunneled, e.g., PleurX-type): allows outpatient intermittent home drainage, reduces hospitalizations, improves quality of life; can also be connected to a Pleur-evac system and managed as a standard chest tube during the acute/ICU phase of illness, then transitioned to intermittent outpatient drainage
• Choice between pleurodesis and indwelling catheter depends on lung re-expandability (trapped lung favors indwelling catheter), performance status, and patient preference

13. Organ Support

Supplemental oxygen as needed; treat sepsis physiology aggressively if empyema-driven (fluid resuscitation, vasopressors, source control via drainage per Surviving Sepsis principles); standard supportive ICU care.

14. Consultation Matrix

15. Monitoring Framework

Serial clinical/radiographic reassessment of effusion size and drainage; chest tube output and character trend; fever curve and inflammatory marker trend for infectious effusions; watch for re-expansion pulmonary edema after large-volume drainage.

16. ICU Bundle Checklist (Daily)

17. Complications

Empyema progression to organized/chronic stage with trapped lung, re-expansion pulmonary edema (rapid large-volume drainage), pneumothorax/bleeding from thoracentesis or tube placement, recurrent malignant effusion despite pleurodesis, catheter-related infection (indwelling catheters). Prevention: ultrasound guidance for all procedures, timely recognition of complicated parapneumonic criteria to avoid progression to organized empyema, controlled drainage rate for large effusions. Rescue: VATS decortication for organized empyema, repeat pleurodesis or catheter exchange for recurrent malignant effusion.

18. Escalation & De-escalation

Escalate: any complicated parapneumonic criterion met -> tube thoracostomy; failure of tube + fibrinolytics -> VATS/thoracotomy referral.

De-escalate: resolving effusion, afebrile, tube output minimal with re-expanded lung -> remove tube per standard criteria (no air leak, minimal output, lung re-expanded).

19. ICU Discharge Criteria

Effusion drained/stable, no respiratory compromise, infection source controlled (afebrile, antibiotics on definitive course), chest tube removed or transitioned to outpatient-manageable indwelling catheter, malignancy-related effusion has a defined longer-term management plan and oncology follow-up.

20. Documentation & Medicolegal Checklist

21. Key Guidelines

British Thoracic Society (BTS) Pleural Disease Guidelines (including guidance for malignant pleural effusion management and ultrasound-guided procedures); American College of Chest Physicians consensus on parapneumonic effusion/empyema management.

22. Landmark Trials

• MIST2 trial: intrapleural tPA + DNase vs either alone vs placebo in pleural infection — combination therapy improved fluid drainage, reduced surgical referral and hospital stay.
• Colice GL. Medical and surgical treatment of parapneumonic effusions. Chest. 2000;118:1158-1171 — foundational algorithm underpinning current complicated-effusion criteria.

23. Controversies

Optimal chest tube size for empyema/complicated parapneumonic effusion remains debated — emerging evidence supports small-bore tubes as equally effective to large-bore, but practice variation persists, particularly for thick frank pus. Threshold and technique for indwelling catheter vs pleurodesis in malignant effusion is individualized without a single preferred universal approach. Management of idiopathic effusions (~20% of cases) after negative workup lacks strong evidence-based guidance beyond conservative observation.

24. References

1. Wayne M, Chen AC. Pleural Disorders in the Intensive Care Unit. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 17).
2. Sattler L, Chenna PR. Thoracentesis. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 84).
3. Patel TM, Chenna PR. Chest Tube Insertion. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 81).
4. Colice GL. Medical and surgical treatment of parapneumonic effusions. Chest. 2000;118:1158-1171.
5. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection (MIST2). N Engl J Med. 2011;365(6):518-526.
6. Antunes G, Neville E, Duffy J, et al. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58(Suppl 2):ii29-ii38.